Stockscreener 앱 받기
2.00
8.70%
0.16
전일 마감가:
$1.84
열려 있는:
$1.79
하루 거래량:
678.82K
Relative Volume:
0.42
시가총액:
$62.10M
수익:
$317.00K
순이익/손실:
$-53.47M
주가수익비율:
-1.0363
EPS:
-1.93
순현금흐름:
$-49.31M
1주 성능:
+22.32%
1개월 성능:
-1.96%
6개월 성능:
+41.84%
1년 성능:
-70.15%
1일 변동 폭
$1.79
$2.08
1주일 범위
$1.56
$2.08
52주 변동 폭
$1.00
$7.92
Immuneering Corp Stock (IMRX) Company Profile
명칭
Immuneering Corp
전화
617-500-8080
주소
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
IMRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
2.00 | 62.10M | 317.00K | -53.47M | -49.31M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-13 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2024-03-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-03-15 | 재확인 | Needham | Buy |
| 2024-03-15 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-12-01 | 개시 | Needham | Buy |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-04-19 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-04-19 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-03-30 | 개시 | Mizuho | Neutral |
| 2023-02-03 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2022-07-08 | 개시 | Chardan Capital Markets | Buy |
| 2022-04-01 | 개시 | Oppenheimer | Outperform |
| 2022-01-07 | 개시 | Piper Sandler | Overweight |
모두보기
Immuneering Corp 주식(IMRX)의 최신 뉴스
Morgan Stanley sees better opportunities, downgrades Immuneering shares to Underweight - Investing.com
Morgan Stanley upgrades PTC, cuts Immuneering, Amicus (PTCT:NASDAQ) - Seeking Alpha
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday? - Yahoo Finance
Immuneering (NASDAQ:IMRX) Stock Rating Lowered by Morgan Stanley - MarketBeat
FDA fast tracks Immuneering's melanoma treatment - Investing.com
Immuneering to Present Pipeline and Strategy at Piper Sandler Healthcare Conference - StockTitan
Immuneering shares retain Outperform rating amid Phase 2a progress for IMM-1-104 - Investing.com
Brokerages Set Immuneering Co. (NASDAQ:IMRX) Price Target at $12.60 - Defense World
Immuneering Leads The Pack Of 3 US Penny Stocks To Monitor - Yahoo Finance
Immuneering Co. (NASDAQ:IMRX) Receives $12.60 Consensus Target Price from Brokerages - MarketBeat
Immuneering Corp. Reports Q3 Loss, Highlights Progress - TipRanks
Immuneering (NASDAQ:IMRX) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
Immuneering Reports Promising Cancer Drug Results, Secures FDA Fast Track Status - StockTitan
Short Interest in Immuneering Co. (NASDAQ:IMRX) Declines By 6.7% - MarketBeat
Immuneering Co. (NASDAQ:IMRX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug - Yahoo Finance
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Uncovering the Potential of Immuneering Corp (IMRX) Stock - The InvestChronicle
Nasdaq Insurance Index (INSR) QuotePress Release - The Globe and Mail
FDA grants orphan drug status to Immuneering's cancer treatment - Investing.com
FDA grants orphan drug status to Immuneering's cancer treatment By Investing.com - Investing.com Canada
Financial Health Check: Examining Immuneering Corp (IMRX)’s Key Ratios - The Dwinnex
Here's Why We're A Bit Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Situation - Yahoo Finance
Renaissance Technologies LLC Takes Position in Immuneering Co. (NASDAQ:IMRX) - MarketBeat
IMRX’s Stochastic Averages Dip: Analyzing Immuneering Corp’s Stock Performance - The InvestChronicle
Marshall Wace LLP Makes New Investment in Immuneering Co. (NASDAQ:IMRX) - MarketBeat
The time has not yet come to remove your chips from the table: Immuneering Corp (IMRX) - SETE News
A stock that deserves closer examination: Immuneering Corp (IMRX) - US Post News
Immuneering Corp’s Market Journey: Closing Strong at 2.47, Up 4.22 - The Dwinnex
Immuneering stock maintains Outperform rating on positive prospects - Investing.com
How does Immuneering Corp (IMRX) change from a tortoise to a hare? - SETE News
Understanding the Risks of Investing in Immuneering Corp (IMRX) - Knox Daily
Immuneering Corp (IMRX) Stock: A Year of Decreases and Increases - The InvestChronicle
Immuneering Co. (NASDAQ:IMRX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Immuneering Corp (IMRX)’s stock chart: A technical perspective - US Post News
Ratio Revelations: Immuneering Corp (IMRX)’s Financial Metrics in the Spotlight - The Dwinnex
Biotech Surges Premarket Following Positive Phase 2a Observations - MSN
Immuneering Corp (IMRX) Recovers 161.00% From Low: Sitting In The Catbird Seat? - Stocks Register
Immuneering Corp [IMRX] stock for 1,160,181 USD was sold by Cormorant Asset Management, LP - Knox Daily
You might want to take a look at Immuneering Corp (IMRX) now - SETE News
Immuneering Corp [IMRX] Insider Cormorant Asset Management, LP sells 400,000 Shares - Knox Daily
Inogen: Upside Seems Limited After Big Move Up (NASDAQ:INGN) - Seeking Alpha
Immune Price Drop Is An Entry Opportunity - Top Buzz Times
IMUX’s 2023 Market Saga: Unraveling the Story of Gains and Losses - The InvestChronicle
Analytical Overview: ImmunityBio Inc (IBRX)’s Ratios Tell a Financial Story - The Dwinnex
Market Momentum Report: Immunic Inc (IMUX)’s Negative Close at 1.60 - The Dwinnex
Inflection Point Acquisition Corp. II (NASDAQ:IPXX) Shares Bought by Berkley W R Corp - MarketBeat
Armored car company tires reverse domain name hijacking - Domain Name Wire
Daily Market Movement: Immuneering Corp (IMRX) Sees a -10.59 Decrease, Closing at 2.87 - The Dwinnex
IOH announces stock split to enhance investor participation - Telecompaper EN
Impax Asset Management Group (LON:IPX) Stock Passes Below Fifty Day Moving Average of $383.00 - MarketBeat
Immuneering Corp (IMRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):